Program
Abiraterone Acetate
Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.
Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 414 open or running | phase 4since Mar 27, 2015 | May 11, 2007 | none ahead |
| Jiangsu HengRui Medicine | 32 open or running | phase 2since Apr 25, 2021 | Apr 25, 2021 | Dec 2026phase 2 · NCT06568094 |
| Sun Pharmaceutical Industries | 31 open or running | phase 2since Mar 25, 2016 | Mar 25, 2016 | Dec 31, 2027phase 2 · NCT05422911 |
| Sanofi | 20 open or running | phase 4since Jun 26, 2015 | Jan 4, 2012 | none ahead |
| Boryung Pharmaceutical | 10 open or running | phase 1since May 12, 2021 | May 12, 2021 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 3since Aug 11, 2019 | Aug 11, 2019 | none ahead |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| zentiva-k-s | 10 open or running | phase 1since Mar 2, 2020 | Mar 2, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since May 11, 2007.
- Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more
- Mar 25, 2016Sun Pharmaceutical Industries’ first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02737332 · 53 enrolled · United States
- Oct 31, 2016Phase 2 study in Prostatic NeoplasmsSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
- Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
- Aug 11, 2019Sino Biopharmaceutical’s first study: phase 3 study in Metastatic Castration Resistant Prostate CancerNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04056754 · 268 enrolled · China
- Mar 2, 2020zentiva-k-s’ first study: phase 1 study in PharmacokineticsNew to zentiva-k-szentiva-k-s · NCT04295161 · 33 enrolled · United Kingdom
- Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
- Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
- Dec 7, 2020Sumitomo Pharma’s first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
- Apr 25, 2021Jiangsu HengRui Medicine’s first study: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)New to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04862091 · 69 enrolled · China
- May 12, 2021Boryung Pharmaceutical’s first study: phase 1 study in Prostatic NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04889651 · 40 enrolled · Korea, Republic of
- Jun 9, 2022Phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911 · 192 planned · United States
- Oct 13, 2023Phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990 · 660 planned
- Aug 21, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094 · 100 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094
- Dec 31, 2027Primary completion: phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911
- Dec 2028Primary completion: phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990
TargetBeta
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06568094Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 100 |
| NCT06099990Neoplasm Metastasis | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 2028 | 660 |
| NCT05422911Neoplasm Metastasis · United States | 2 | Recruiting | Sun Pharmaceutical Industries | Dec 31, 2027 | 192 |
| NCT04889651Prostatic Neoplasms · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jun 8, 2021 | 40 |
| NCT04862091Metastatic Castration-resistant Prostate Cancer (mCRPC) · China | 2 | Completed | Jiangsu HengRui Medicine | Oct 21, 2021 | 69 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04577833Prostatic Neoplasms · United States, Belgium, France and more | 1 | Active, not recruiting | Johnson & Johnson | Oct 15, 2021 | 136 |
| NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 7, 2025 | 696 |
| NCT04295161Pharmacokinetics · United Kingdom | 1 | Completed | zentiva-k-s | Nov 8, 2019 | 33 |
| NCT04056754Metastatic Castration Resistant Prostate Cancer · China | 3 | Completed | Sino Biopharmaceutical | Mar 14, 2018 | 268 |
| NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 8, 2021 | 765 |
| NCT02962284Prostatic Neoplasms | 2 | Completed | Sun Pharmaceutical Industries | Mar 2018 | 20 |
| NCT02737332Prostatic Neoplasms · United States | 2 | Completed | Sun Pharmaceutical Industries | Feb 27, 2017 | 53 |
| NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more | 4 | Completed | Sanofi | Mar 27, 2019 | 255 |
| NCT02405858Metastatic Castration-Resistant Prostate Cancer · Japan | 4 | Completed | Johnson & Johnson | Dec 31, 2017 | 51 |
| NCT02230046Healthy · United States | 1 | Completed | Johnson & Johnson | Nov 2014 | 102 |
| NCT02217566Prostatic Neoplasms · Brazil | 2 | Completed | Johnson & Johnson | Oct 26, 2018 | 46 |
| NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more | 1 | Active, not recruiting | Johnson & Johnson | Jun 27, 2016 | 57 |
| NCT02001571Prostatic Neoplasms · United States | 1 | Completed | Johnson & Johnson | Apr 2010 | 24 |
| NCT01873001Healthy Volunteers · Belgium | 1 | Completed | Johnson & Johnson | Jul 2013 | 16 |
| NCT01795703Prostatic Neoplasms · Japan | 2 | Completed | Johnson & Johnson | Oct 2014 | 47 |
| NCT01756638Prostatic Neoplasms · Japan | 2 | Completed | Johnson & Johnson | Oct 17, 2014 | 48 |
| NCT01715285Prostatic Neoplasms · Argentina, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Oct 31, 2016 | 1,209 |
| NCT01715259Renal Insufficiency · United States | 1 | Completed | Johnson & Johnson | Jan 2010 | 16 |
| NCT01798628Healthy Volunteers | 1 | Completed | Johnson & Johnson | Oct 2009 | 36 |
| NCT01695135Prostatic Neoplasms · China | 3 | Completed | Johnson & Johnson | Jun 20, 2014 | 214 |
| NCT01685983Prostatic Neoplasms · Korea, Republic of, Taiwan | 2 | Completed | Johnson & Johnson | Jan 24, 2013 | 82 |
| NCT01678573Healthy · China | 1 | Completed | Johnson & Johnson | Sep 2012 | 15 |
| NCT01664728Prostatic Neoplasms · United Kingdom | 1 | Completed | Johnson & Johnson | Feb 2009 | 54 |
| NCT01640093Healthy Participants · United States | 1 | Completed | Johnson & Johnson | Jul 2012 | 32 |
| NCT01591122Prostatic Neoplasms · China, Malaysia, Russian Federation and more | 3 | Completed | Johnson & Johnson | Dec 31, 2016 | 313 |
| NCT01655147Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2012 | 19 |
| NCT01517802Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Apr 22, 2021 | 32 |
| NCT01575587Pharmacology · United States | 1 | Completed | Johnson & Johnson | May 2012 | 51 |
| NCT01588782Healthy Volunteers · Belgium | 1 | Completed | Johnson & Johnson | Feb 2012 | 20 |
| NCT01511536Prostatic Neoplasms · United States, France, United Kingdom | 2 | Completed | Sanofi | Jul 2014 | 38 |
| NCT01495910Congenital adrenal hyperplasia due to 21 hydroxylase deficiency · United States | 1 | Completed | Johnson & Johnson | Feb 2013 | 6 |
| NCT01424930Prostatic Neoplasms · Canada | 2 | Completed | Johnson & Johnson | Apr 2013 | 25 |
| NCT01381874Breast Neoplasms · United States, Belgium, France and more | 2 | Completed | Johnson & Johnson | Jul 28, 2014 | 297 |
| NCT01362764Healthy Volunteers | 1 | Completed | Johnson & Johnson | Jun 2011 | 30 |
| NCT01314118Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Dec 24, 2013 | 131 |
| NCT01186484Prostatic Neoplasms · Japan | 1 | Completed | Johnson & Johnson | Oct 2, 2014 | 27 |
| NCT01017939Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Jun 2010 | 34 |
| NCT00924469Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Feb 2012 | 58 |
| NCT00910754Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Nov 2009 | 33 |
| NCT00887198Prostatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Mar 31, 2014 | 1,088 |
| NCT00638690Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Johnson & Johnson | Aug 2010 | 1,195 |
| NCT00600535Prostatic Neoplasms · United States, United Kingdom | 1 | Completed | Johnson & Johnson | Mar 2012 | 31 |
| NCT00544440Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Aug 2012 | 57 |
| NCT00485303Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Johnson & Johnson | Oct 2011 | 58 |
| NCT00474383Prostatic Neoplasms · United States, United Kingdom | 2 | Completed | Johnson & Johnson | Aug 2011 | 47 |
| NCT00473746Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Dec 2012 | 66 |
| NCT00473512Prostatic Neoplasms · United Kingdom | 2 | Completed | Johnson & Johnson | Nov 2008 | 54 |
How it is read
Names in the registry
- “Abiraterone acetate”, 24 entries
- “Abiraterone”, 10 entries
- “Abiraterone Acetate”, 5 entries
- “abiraterone acetate”, 2 entries
- “Abiraterone acetate (Treatment B)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 43 studies
- Neoplasm Metastasis, 2 studies
- Breast Neoplasms, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.